In this news roundup, take a look back at top moments from the pharmaceutical industry in January 2026.

The UK and Japanese governments have announced a sweeping pharmaceutical and technology partnership.

The programme will focus on pancreatic, ovarian and oesophageal cancers – three indications that often spread silently.

With two new Nipah virus cases confirmed, the pressure is mounting on the pharmaceutical industry to manufacture a vaccine.

Pascal Soriot, CEO, AZ, hailed the investment as the start of “an exciting next chapter” for the company in China.

The Office of Inspector General’s bulletin provides a framework for pharma companies selling prescription drugs direct-to-consumers (DTC).

The CMS has unveiled the 15 high-cost medications selected for the next phase of the Medicare Drug Price Negotiation Program.

A new study shows how limitations in electronic lab notebooks (ELNs) are driving pharma R&D teams to use AI tools, raising privacy concerns.